Efficacy Result from a Phase 2, Double-Blind, Placebo-Controlled Study of CX-8998 a State-Dependent T-Type Calcium (Cav3) Channel Modulator in Essential Tremor Patients (T-CALM)

被引：0
|
作者：
Papapetropoulos, Spyros [1 ]
Lee, Margaret [1 ]
Boyer, Stacey [1 ]
Krouse, Andrew [1 ]
Pahwa, Rajesh [2 ]
Lyons, Kelly [2 ]
Ondo, William [3 ]
Jinnah, H. [4 ]
Elble, Rodger [5 ]
机构：
[1] Cavion Inc, Wellesley, MA USA
[2] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[3] Methodist Neurol Inst, Houston, TX USA
[4] Emory Univ, Atlanta, GA 30322 USA
[5] Southern IL Univ, Sch Med, Springfield, IL USA
来源：
NEUROLOGY | 2019年 / 92卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S4.008
引用
收藏
页数：3
相关论文
共 41 条
  • [1] Proof-of-Concept, Double-Blind, Placebo-Controlled Study for CX-8998, a State-Dependent T-Type Calcium (TTCC) Modulator in Essential Tremor Patients (T-CALM): Efficacy and Safety Results
    Papapetropoulos, Spyros
    Boyer, Stacey
    Lee, Margaret S.
    [J]. NEUROTHERAPEUTICS, 2019, 16 (03) : 917 - 917
  • [2] Efficacy and Safety of the T-Type Calcium Channel Modulator CX-8998 in T-CALM, a Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial in Participants with Essential Tremor
    Ondo, William
    Papapetropoulos, Spyros
    Lee, Margaret S.
    Versavel, Stacey
    Krouse, Andrew
    Newbold, Evan
    Jinnah, Hyder A.
    Pahwa, Rajesh
    Lyons, Kelly E.
    Zesiewicz, Theresa
    Hedera, Peter
    Handforth, Adrian
    Elder, Jenna
    Versavel, Mark
    Elble, Rodger
    [J]. ANNALS OF NEUROLOGY, 2020, 88 : S175 - S175
  • [3] A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of CX-8998, a Selective Modulator of the T-Type Calcium Channel in Inadequately Treated Moderate to Severe Essential Tremor: T-CALM Study Design and Methodology for Efficacy Endpoint and Digital Biomarker Selection
    Papapetropoulos, Spyros
    Lee, Margaret S.
    Boyer, Stacey
    Newbold, Evan J.
    [J]. FRONTIERS IN NEUROLOGY, 2019, 10
  • [4] Efficacy and safety of CX-8998 in T-CALM, a randomized, double-blind, placebo-controlled, phase 2a trial in participants with essential tremor: subgroup analysis by baseline tremor severity
    Jinnah, H.
    Papapetropoulos, S.
    Lee, M.
    Versavel, S.
    Newbold, E.
    Pahwa, R.
    Lyons, K.
    Elble, R.
    Ondo, W.
    Zesiewicz, T.
    Hedera, P.
    Handforth, A.
    Elder, J.
    Versavel, M.
    [J]. MOVEMENT DISORDERS, 2020, 35 : S687 - S687
  • [5] Efficacy and Safety of CX-8998 in T-CALM, a Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial in Participants With Essential Tremor: Subgroup Analysis by Baseline Tremor Severity
    Jinnah, Hyder A.
    Papapetropoulos, Spyros
    Lee, Margaret
    Boyer, Stacey
    Newbold, Evan
    Pahwa, Rajesh
    Lyons, Kelly E.
    Elble, Rodger
    Ondo, William
    Zesiewicz, Theresa
    Hedera, Peter
    Handforth, Adrian
    Elder, Jenna
    Versavel, Mark
    [J]. NEUROLOGY, 2020, 94 (15)
  • [6] CX-8998: a Novel, State-Dependent Cav3 Channel Antagonist in Phase 2 Development for Tremor and Epilepsy
    Papapetropoulos, Spyr
    Boyer, Stacey
    Lee, Margaret
    [J]. NEUROTHERAPEUTICS, 2018, 15 (03) : 832 - 832
  • [7] A Phase 2 Efficacy Study of an Oral, Potent and Selective T-Type Calcium (Cav3) Modulator in Essential Tremor Patients (T-CALM): Design and Dose Selection Rationale
    Papapetropoulos, Spiridon
    Maricich, Yuri
    Lee, Margaret
    Boyer, Stacey
    Silver, Bruce
    [J]. NEUROLOGY, 2018, 90
  • [8] A Phase 2 Efficacy Study of CX-8998, a Potent and Selective T-Type Calcium (Cav3) Modulator in Parkinson's disease Tremor (PDT) Patients: Design and Dose-Selection Rationale
    Papapetropoulos, S.
    Lee, M.
    Boyer, S.
    Versavel, M.
    [J]. MOVEMENT DISORDERS, 2018, 33 : S14 - S14
  • [9] A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the T-Type Calcium Channel Blocker ABT-639 in an Intradermal Capsaicin Experimental Pain Model in Healthy Adults
    Wallace, Mark
    Duan, Rachel
    Liu, Wei
    Locke, Charles
    Nothaft, Wolfram
    [J]. PAIN MEDICINE, 2016, 17 (03) : 551 - 560
  • [10] Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study
    Seino, Yutaka
    Sasaki, Takashi
    Fukatsu, Atsushi
    Ubukata, Michito
    Sakai, Soichi
    Samukawa, Yoshishige
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (07) : 1245 - 1255
12345